Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

NCT03258008 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Closed the trial for infeasibility due to slow accrual

Conditions

Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
Malignant Neoplasms of Lip Oral Cavity and Pharynx
Oropharyngeal Cancer

Interventions

DRUG: Utomilumab
BIOLOGICAL: ISA101b

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]